Aaron Endsley - Certara Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

POS-109 INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IgA NEPHROPATHY

Jonathan Barratt,Billy Hour,Cailin Sibley,Angelique Mittan,Suzanne Roy,Colleen Stromatt,Aaron Endsley,Jeannette Lo,Alan Glicklich

Kidney international reports（2022）

引用11浏览0引用

MO212: Updated Interim Results of A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IGA Nephropathy

Jonathan Barratt,Laura Kooienga,Billy Hour,Irfan Agha,Brian Schwartz,Bess Sorensen,Jeannette Lo,Andrew King, Taher Sathaliya,Sai Prasad N. Iyer,Aaron Endsley,Alan Glicklich

Nephrology, dialysis, transplantation/Nephrology dialysis transplantationno. Supplement_3 (2022)

引用1浏览0引用

POS-108 A PHASE 1/2, MULTICENTER TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IgA NEPHROPATHY

J. Barratt, B. Schwartz, B. Sorensen,S. Roy,C. Stromatt, M. MacDonald, J. Tolentino,S.P. IYER,A. Endsley, J. Lo,A. Glicklich

Kidney international reportsno. 2 (2022): S45-S46

引用0浏览0引用

Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial

Jonathan Barratt,Billy T. Hour,Brian S. Schwartz,Bess Sorensen,Suzanne E. Roy, Colleen L. Stromatt, Margaret MacDonald,Aaron N. Endsley,Jeannette Lo,Alan Glicklich,Andrew J. King

Journal of the American Society of Nephrologyno. 10S (2021): 509-509

引用0浏览0引用

First in Human Evaluation and Dosimetry Calculations for Peptide 124 I-p5+14—a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT Imaging

Jonathan S. Wall,Emily B. Martin,Aaron Endsley,Alan C. Stuckey,Angela D. Williams,Dustin Powell,Bryan Whittle,Sarah Hall,Tyler R. Lambeth,Ryan R. Julian,Michael Stabin,Ronald H. Lands,Stephen J. Kennel

Mol Imaging Biol（2021）

引用6浏览0WOS引用

MO286DESIGN OF A PH1, MULTICENTER TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PK/PD OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGAN AND A MULTICENTER, OPEN-LABEL EXTENSION STUDY FOR IGAN PATIENTS WHO PARTICIPATED IN A PRIOR TRIAL OF BION-1301

Jonathan Barratt,Angelique Mittan,Suzanne Roy,Cailin Sibley,Colleen Stromatt,Aaron Endsley,Jeannette Lo,Alan Glicklich

Nephrology, dialysis, transplantation/Nephrology dialysis transplantation（2021）

引用0浏览0引用

POS-144 A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, PARALLEL GROUP SAFETY AND BIOAVAILABILITY STUDY OF BION-1301 ADMINISTERED BY INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) ROUTES

C. SIBLEY, A. Mittan,A. Endsley, S. Roy, J. Lee, S. Lewis,J. Lo,A. Glicklich

Kidney international reports（2021）

引用0浏览0引用

P0379bion-1301, a fully blocking antibody targeting april for the treatment of iga nephropathy: assessment of safety, pharmacokinetics and pharmacodynamics in long-term nonclinical studies

Joost Kreijtz,Peter Van Zandvoort,Jos Van de Crommert, Maarten Friesen,Jeannette Lo,Aaron Endsley, Veronique Lauriault, Thomas Mueller,Andrea Van Elsas

Nephrology Dialysis Transplantationno. Supplement_3 (2020)

引用0浏览0引用

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers

Jeannette Lo, Sharon Yavrom, Jessy Fan,Aaron N. Endsley,Tamara Schroeder,Jonathan Barratt, David M. Essayan

Journal of the American Society of Nephrologyno. 10S (2020): 574-574

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn